Eli Lilly and Company (NYSE:LLY) is considered one of the best stocks for long-term investment, with a Buy rating from Guggenheim analyst Seamus Fernandez and a price target of $875.00.

Following its fiscal Q2 2025 earnings report on August 7, Eli Lilly and Company (NYSE:LLY) saw a 38% revenue growth to $15.56 billion, driven by volume growth from Zepbound and Mounjaro.

Eli Lilly and Company (NYSE:LLY) raised its 2025 full-year revenue guidance by $1.5 billion to the $60 billion to $62 billion range, along with an increase in reported EPS guidance to $20.85 to $22.10.

Eli Lilly and Company (NYSE:LLY) specializes in developing, manufacturing, discovering, and selling pharmaceutical products across various therapeutic areas like oncology, diabetes, and neuroscience.

While Eli Lilly and Company (NYSE:LLY) presents investment potential, some believe that certain AI stocks offer higher upside potential with lower downside risk. For more information, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Guggenheim Maintains a Buy Rating on Eli Lilly and Company (LLY), Sets a $875 PT